INSULIN DETEMIR IN ROUTINE CLINICAL PRACTICE: A 26-WEEK FOLLOW-UP IN TYPE 1 DIABETIC PATIENTS FROM THE BELGIAN PREDICTIVE COHORT

REFERENCES

• DCCT Research Group. The effect of intensive treatment of dia-betes on the development and progression of long-term com-plications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) study research group. Intensive diabetes treatment and cardiovascu-lar disease in patients with type 1 diabetes. N EngIJ Med 2005; 353: 2643–53.
   PubMed Web of Science ®Google Scholar
• DCCT Research Group. Hypoglycaemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271–86.
   Web of Science ®Google Scholar
• Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Tria JAMA 1998; 280: 140–6.
   Google Scholar
• Hirsch IB. Insulin analogues. N Engl J Med 2005; 352 : 174–83.
   PubMed Web of Science ®Google Scholar
• Kurtzhals P. Engineering predictability and protraction in a ba-sal insulin analogue: the pharmacology of insulin detemir. Intl Obes 2004; 28 (suppl 2): 523–58.
   Google Scholar
• Vague P, Selam JL, Skeie S, et al. Insulin detemir is associated with more predictable glycaemic control and reduced risk of hypoglycaemia than NPH insulin in patients with type 1 dia-betes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590–6.
   PubMed Web of Science ®Google Scholar
• De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in ba-sal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73–82.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) ver-sus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabe-tes. Diabetologia 2004; 47 (4): 622–9.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001; 24:296–301.
   PubMed Web of Science ®Google Scholar
• Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in peo-ple with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004; 27 (5): 1081–7.
   PubMed Web of Science ®Google Scholar
• Russel-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with diabetes mellitus us-ing a basal-bolus regimen. Clin Ther 2004; 26 (5): 724-36. Pieber T,Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24 (6): 635–42.
   Google Scholar
• LLiddeke Hi, Sreenan S, Aczel S, et al. on behalf of the PREDIC-TIVE Study Group. PREDICTIVE - a global, prospective obser-vational study to evaluate insulin detemir treatment in type 1 and 2 diabetes: baseline characteristics and predictors of hy-poglycaemia from the European cohort. Diabetes Obes Metab 2007; 9 (3): 428–34.
   Web of Science ®Google Scholar
• Dornhorst A, LLiddeke HJ, Sreenan S, et al. on behalf of the PRE-DICTIVE study group. Safety and efficacy of insulin detemir in clinical practice: 14-weeks follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Intl Clin Pract 2007; 61(3): 523–8.
   Web of Science ®Google Scholar
• Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, LLid-deke Hi. Insulin detemir improves glycaemic control with less weight gain in patients with type 2 who were insulin naïve or treated with NPH or glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Obes Metab 2007; 9 (3): 418–27.
   PubMed Web of Science ®Google Scholar
• Mathieu C. Can we reduce hypoglycaemia with insulin de-temir? Intl Obes 2004; 28 (Suppl.2): S35–S40.
   Google Scholar
• Summary of revisions for the 2008 clinical practice recommen-dations. Diabetes Care 2008; 31 (suppl 1): S3–S4.
   Google Scholar
• Heise T, Nosek L, Biilmann ROnn B, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53 (6): 1614–20.
   PubMed Web of Science ®Google Scholar
• Fritsche A, Häring H. At last, a weight neutral insulin? Intl Obes 2004; 28 (suppl 2): S41–S6.
   PubMedGoogle Scholar